Incidence of male breast cancer in scandinavia, 1943–1982

Ewertz, Marianne; Holmberg, Lars; Karjalainen, Sakari; Tretli, Steinar; Adami, Hans‐Olov

doi:10.1002/ijc.2910430107

Cited by 68 publications

(40 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, male reproductive tract development and testicular functions are undergoing important modifications which could be the result of changes in our environment. Finally, another study has shown an increase in male breast cancer, a rare pathology, in four Scandinavian countries (Ewetz et al 1989). The risk of breast cancer increases in women over fifty years of age, probably because they have been exposed to active estradiol for a long period of time (Marshall 1993).…”

Section: Introductionmentioning

confidence: 96%

Two complementary bioassays for screening the estrogenic potency of xenobiotics: recombinant yeast for trout estrogen receptor and trout hepatocyte cultures

Petit¹,

Goff²,

Cravedi³

et al. 1997

Journal of Molecular Endocrinology

173

View full text Add to dashboard Cite

A relation between the chemical structure of a xenobiotic and its steroidal action has not yet been clearly established. Thus, it is not possible to define the estrogenic potency of different xenobiotics. An assessment may be accomplished by the use of different bioassays. We have previously developed a yeast system highly and stably expressing rainbow trout estrogen receptor (rtER) in order to analyze the biological activity of the receptor. The recombinant yeast system appears to be a reliable, rapid and sensitive bioassay for the screening and determination of the direct interaction between ER and estrogenic compounds. This system was used in parallel with a more elaborate biological system, trout hepatocyte aggregate cultures, to examine the estrogenic potency of a wide spectrum of chemicals commonly found in the environment. In hepatocyte cultures, the vitellogenin gene whose expression is principally dependent upon estradiol was used as a biomarker. Moreover, competitive binding assays were performed to determine direct interaction between rtER and xenobiotics. In our study, 50%of the 49 chemical compounds tested exhibited estrogenic activity in the two bioassays: the herbicide diclofop-methyl; the fungicides biphenyl, dodemorph, and triadimefon; the insecticides lindane, methyl parathion, chlordecone, dieldrin, and endosulfan; polychlorinated biphenyl mixtures; the plasticizers or detergents alkylphenols and phthalates; and phytoestrogens. To investigate further biphenyl estrogenic activity, its principal metabolites were also tested in both bioassays. Among these estrogenic compounds, 70% were able to activate rtER in yeast and hepatocytes with variable induction levels according to the system. Nevertheless, 30% of these estrogenic compounds exhibited estrogenic activity in only one of the bioassays, suggesting the implication of metabolites or different pathways in the activation of gene transcription. This paper shows that it is important to combine in vivo bioassays with in vitro approaches to elucidate the mechanism of xenoestrogen actions.

show abstract

Section: Introductionmentioning

confidence: 96%

Two complementary bioassays for screening the estrogenic potency of xenobiotics: recombinant yeast for trout estrogen receptor and trout hepatocyte cultures

Petit¹,

Goff²,

Cravedi³

et al. 1997

Journal of Molecular Endocrinology

173

View full text Add to dashboard Cite

show abstract

“…3 The prevalence of male breast cancer increases with age; the average age at diagnosis is 60 years old, which is 10 years greater than in women. 4 The incidence of breast cancer in men varies considerably by geographic location.…”

Section: Introductionmentioning

confidence: 99%

Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening

Lee

Jones

2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Synchronous or metachronous occurrences of both prostate cancer and male breast cancer are rarely reported, but provide insight into their hormonal and genetic biology. We sought to determine the incidence of prostate cancer in male breast cancer patients at our institution, and to examine estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu receptor (HR) status in these patients. A retrospective review was conducted of male breast cancer patients from 1990 to 2006. Histopathologic characteristics and hormone receptor expression was obtained. In 69 patients with male breast cancer, 12 (17%) also had a diagnosis of prostate cancer. Nine had ER-positive status and three were unreported. PR status was positive in 5, whereas 3 had PR-negative status. HR status was positive in 1, whereas 5 had HR-negative status. Male breast cancer patients in this cohort have an incidence of prostate cancer higher than would be predicted in the general population; this risk factor has implications for careful prostate cancer screening.

show abstract

“…[1][2][3][4][5][6][7][8][9][10] The incidence of MBC, however, is rising and continues to increase by 1.1% yearly. 10 The American Cancer Society estimates that, in 2006, 1760 men will be diagnosed with breast cancer, and 460 men will die of the disease.…”

mentioning

confidence: 99%

Male breast cancer in the veterans affairs population

Nahleh

Srikantiah

Safa

et al. 2007

Cancer

128

View full text Add to dashboard Cite

BACKGROUND. The incidence of male breast cancer (MBC) continues to rise. The Veterans Affairs (VA) Central Cancer Registry (VACCR) provides a unique source for the study of MBC. The objective of this retrospective analysis was to compare the characteristics and outcome of patients with MBC and patients with female breast cancer (FBC) in the VA population. METHODS. VACCR data were used to analyze the database of VA patients who had breast cancer diagnosed between 1995 and 2005. It includes 120 VA medical centers. Primary site codes were identified for breast cancer (500–508). Data were entered and analyzed using biostatistical software. RESULTS. In total, 3025 patients' records were reviewed, and 612 patients who had MBC were compared with 2413 patients who had FBC. The mean age at diagnosis was 67 years for patients with MBC and 57 years for patients with FBC (P < .005). More patients with MBC were black, and patients with MBC presented with higher disease stage and more lymph node‐positive disease. The dominant histology in MBC was ductal carcinoma. No difference in grade or laterality was observed. Estrogen and progesterone receptor‐positive tumors were more common in MBC compared with FBC. Overall, patients with MBC received less chemotherapy, whereas no statistical difference was observed in the use of hormone treatment. The median overall survival for patients who had MBC was 7 years compared with 9.8 years for patients who had FBC (log‐rank test; P < .005). There was no statistically significant difference in median survival for patients with stage III disease and stage IV disease. However, the median survival differed significantly for patients with stage I disease and stage II disease. In lymph node‐negative patients, the median survival was 6.1 years for patients with MBC and 14.6 years for patients with FBC (P < .005), whereas the median survival did not differ significantly in lymph node‐positive patients. Using Cox regression analysis age, sex, clinical stage, and lymph node status were independent prognostic factors for survival, whereas race, histology, and grade were not. CONCLUSIONS. To the authors' knowledge, this is the largest series of MBC and FBC to date in the veterans population. The results suggested the presence of differences in the biology, pathology, presentation, ethnicity, and survival between patients with MBC and patients with FBC in the VA population. It is noteworthy that the survival of patients with MBC was inferior for those with early‐stage disease and lymph node‐negative tumors, suggesting that there are differences between the sexes in the pathogenesis and biology of breast cancer. In patients with hormone receptor‐positive MBC, survival was inferior despite similar hormone treatment practices between MBC and FBC. This observational study calls for a better understanding of this disease that would allow new opportunities for specific therapeutic intervention. Cancer 2007. © 2007 American Cancer Society.

show abstract

Incidence of male breast cancer in scandinavia, 1943–1982

Cited by 68 publications

References 14 publications

Two complementary bioassays for screening the estrogenic potency of xenobiotics: recombinant yeast for trout estrogen receptor and trout hepatocyte cultures

Two complementary bioassays for screening the estrogenic potency of xenobiotics: recombinant yeast for trout estrogen receptor and trout hepatocyte cultures

Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening

Male breast cancer in the veterans affairs population

Contact Info

Product

Resources

About